Liquidia (NASDAQ:LQDA) CEO Sells $399,693.04 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 6,428 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $62.18, for a total value of $399,693.04. Following the sale, the chief executive officer directly owned 1,041,667 shares of the company’s stock, valued at $64,770,854.06. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
• On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total value of $1,528,250.00.
• On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $58.65, for a total value of $1,466,250.00.
• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.

Liquidia Stock Down 0.4%

Shares of NASDAQ:LQDA opened at $61.79 on Friday. The business has a 50-day moving average price of $44.53 and a 200 day moving average price of $38.47. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $5.49 billion, a price-to-earnings ratio of 441.35 and a beta of 0.41. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $63.46.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue was up 4187.1% compared to the same quarter last year. Sell-side analysts expect that Liquidia Corporation will post 2.97 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on LQDA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. Finally, BTIG Research lifted their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.88.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently added to or reduced their stakes in the business. Segall Bryant & Hamill LLC purchased a new stake in Liquidia during the first quarter worth approximately $2,111,000. Bank of America Corp DE lifted its stake in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the last quarter. California State Teachers Retirement System lifted its stake in Liquidia by 25.0% during the first quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock worth $2,734,000 after purchasing an additional 14,485 shares during the last quarter. Empowered Funds LLC purchased a new stake in Liquidia during the first quarter worth approximately $3,650,000. Finally, Eversept Partners LP lifted its stake in Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).